Injury guide

Dupixent and eye pain

New eye pain or blurred vision while taking Dupixent needs prompt care. Call your doctor and keep the eye exam and drug records.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202610 sources

This may apply to you if

  • These suggestions help you prepare for a claim check. They are not a firm's acceptance rules.
  • For preparation: note Dupixent use, the reason it was prescribed and the diagnosis you want checked. This does not decide whether a lawyer will accept the case.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

The evidence and its limits

Royal Victoria Infirmary · 2023

Eye surface disease after Dupixent: prospective case series

Design:
Cohort
Participants:
113 included eczema patients; 32 developed eye surface disease; 20 referred to the cornea service
Finding:
Clinician-led eye treatment improved symptoms in this series; no participant stopped Dupixent in the reported series.
Main limitation
Selected UK clinic; no randomized comparison. Original abstract and metadata read, not full paper. Cannot establish a personal cause or justify continuing medicine against current clinical advice.

Read the source: Eye surface disease after Dupixent: prospective case series (opens in a new tab) · Checked Oct 3, 2026

The short answer

What is this eye condition?
Dupixent can be linked to problems at the eye surface. The label warns about eye inflammation. The risk differs across the conditions it treats. [9]
What signs need prompt medical care?
Call your doctor right away for new or worse eye pain, redness or blurred vision. The drug guide also lists changes in vision as serious symptoms. [8]
How are eye problems diagnosed and treated?
The drug label says an eye exam may be needed. Your clinician can decide whether to change the drug or seek more eye care. [9]
What does eye research show?
A UK study found eye problems in 32 of 113 people on Dupixent for eczema. This does not show the risk for all users. [10]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

When it fits this case

  • These suggestions help you prepare for a claim check. They are not a firm's acceptance rules.
  • For preparation: note Dupixent use, the reason it was prescribed and the diagnosis you want checked. This does not decide whether a lawyer will accept the case.

What is this eye condition?

Dupixent can be linked to problems at the eye surface. The label warns about eye inflammation. The risk differs across the conditions it treats.

What signs need prompt medical care?

Call your doctor right away for new or worse eye pain, redness or blurred vision. The drug guide also lists changes in vision as serious symptoms.

Do not wait for a lawsuit check before getting eye care. Tell the doctor which medicine you use and when the eye changes began. Follow emergency instructions from your care team or drug guide.

How are eye problems diagnosed and treated?

The drug label says an eye exam may be needed. Your clinician can decide whether to change the drug or seek more eye care.

Ask what the eye exam found and what follow-up is planned. Bring a list of eye drops and other medicines. Do not choose a new eye treatment from a research paper or lawsuit page.

What does eye research show?

A UK study found eye problems in 32 of 113 people on Dupixent for eczema. This does not show the risk for all users.

The researchers followed patients at one service and used eye exams to assess symptoms. Twenty of the 32 affected patients were sent to a cornea service, which treats the eye's clear front surface.

Symptoms improved with care in the series. None stopped the drug there, but that finding does not overrule a doctor's advice for you. A clinic series cannot prove what caused an individual eye problem.

Does an eye problem qualify for a claim?

The June 2026 federal transfer order concerns skin T-cell cancer claims. An eye problem alone is not the same injury described in that order.

A lawyer can check an eye injury on its own facts. Ask which claim and time limit apply rather than assuming every drug side effect belongs in the same federal case group.

Keep the eye diagnosis distinct from the name of your skin disease. The care record may help explain when the eye condition began and what treatment it required.

What eye and drug records should I keep?

Keep eye exam results and a list of drug doses and dates. Ask your provider for the records you lack, and note any gaps.

You can start with notes about earlier eye problems, changes in sight and the names of your treating doctors. Mark estimates as estimates; an uncertain date is not a reason to invent a precise one.

The federal access rule applies to certain health records with stated exceptions. It does not promise an instant copy of every note. Ask the office about its request process.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. Dupixent JPML transfer order, June 4, 2026Dupixent JPML transfer order, June 4, 2026 · court
  5. Mandel et al: CTCL after dupilumab, 2024Mandel et al: CTCL after dupilumab, 2024 · study
  6. Stuver et al: matched CTCL outcomes, 2024 online/2025 issueStuver et al: matched CTCL outcomes, 2024 online/2025 issue · study
  7. FDA potential-signal table, information as of March 6, 2025FDA potential-signal table, information as of March 6, 2025 · regulator
  8. MedlinePlus: dupilumab injection, revised August 15, 2025MedlinePlus: dupilumab injection, revised August 15, 2025 · regulator
  9. Dupixent prescribing information, revised April 2026
  10. Pradhan et al: prospective eye case series, original abstract

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026